Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
50 hedge funds and large institutions have $74.3M invested in Sinovac Biotech, Ltd in 2014 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 7 closing their positions.
4% less funds holding
Funds holding: 52 → 50 (-2)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
29% less capital invested
Capital invested by funds: $104M → $74.3M (-$29.8M)
80% less call options, than puts
Call options by funds: $135K | Put options by funds: $675K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$943K |
| 2 |
Renaissance Technologies
New York
|
+$870K |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$735K |
| 4 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$710K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$333K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.14M |
| 2 |
Jane Street
New York
|
-$1.6M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$730K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$472K |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$403K |
SVA Hedge Fund Activity: Q2 2014 in Review
50 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2014, worth a combined $74.3M — down 29% from $104M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SVA and 5 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 15 added.
The largest buyer was Goldman Sachs, adding an estimated $943K. The largest seller was Wellington Management Group, cutting an estimated $7.14M.
- 50 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2014, down from 52 in Q1 2014.
- Funds reported $74.3M of Sinovac Biotech, Ltd stock for Q2 2014, down 29% quarter-over-quarter.
- 5 funds opened new Sinovac Biotech, Ltd positions in Q2 2014 and 7 closed out, a net change of -2 holders.
- The largest Sinovac Biotech, Ltd buyer in Q2 2014 was Goldman Sachs, an estimated $943K added.
- The largest Sinovac Biotech, Ltd seller in Q2 2014 was Wellington Management Group, an estimated $7.14M sold.
Based on aggregated 13F filings for Q2 2014.